CWS-Guidance
автор: CWS, Последнее изменение: 2015/06/11 https://kinderkrebsinfo.de/doi/e79368
CWS-Guidance | CWS-guidance for risk adapted treatment of soft tissue sarcoma (STS) and soft tissue tumours in children, adolescents, and young adults. |
---|---|
Формы рака | Soft tissue tumours |
Вид исследования | Therapy-guidance |
Цель исследования |
The CWS-Study-Grpup provides all participating centres of the registry SoTiSar with a threrapy guideline. The" CWS-Guidance" is a guideline for the teatment of patients with a soft-tissue-tumour or sarcoma with the following tumourgroups or clinical situations:
Lokalisierte Rhabdomyosarkome: Im Rahmen der European Soft Tissue Sarcoma Study Group (EpSSG), einem Verbund der drei europäischen Weichteilsarkom-Studiengruppen (CWS, SIOP-MMT und AIEOP STSC, ehemals ICG) wurde im Jahr 2004 Localized rhabdomyosarcoma: Based on the results of the European Soft Tissue Study Group (EpSSG) a new risk grouping system and a standard-therapy for patients with local RMS has been developed in the year 2004 as a Pan European consenus. This therapy, which is actually the best known, is part oft the CWS-Guideline. Other local "RMS-like" tumours:Extraosseous Ewing tumours, Peripheral primitive neuroectodermal tumour, Synovial sarcoma, Undifferentiated sarcoma
Non-rhabdomyosarcoma ("NRSTS")
Metastatic patients
“Second line” Chemotherapy: Possible fpr patients with only partial-response, stable desease or relapsed desease
Fibromatosis and Myxofibromatosis
Pleuropulmonary Blastoma: (in cooperation with the International Pleuropulmonary Blastoma Registry, USA, CWS-Coordinator Dr. Sylvia Kirsch)
Gastrointestinal Stroma Tumour and Dermatofibrosarcoma protuberans: (in cooperation with the European Working Group on Pediatric GISTs, CWS-coordinator PD Dr. Martin Benesch, Graz, Österreich)
The CWS-Guidance contains todays best known, standardised therapy-guideline for different soft-tissue tumours and sarcoma. It is based on the results of the european trials CWS-81, 86, 91, 96 and 2002P and other international trials. For patients with RMS a therapy is recommanded, which was developed in 2004 with experts of the "European paediatric Soft Tissue Study Group" as a european standard. |
Лечение |
The therapy-arms will be stratified accordingly to the tumourtype (Rhabdomyosacoma, RMS-like tumours, Non-RMS-like tumours, other soft-tissue-tumours) and the risk-factors (histology, post surgical stage, tumour site, node involvement, initial tumour size and patients’ age). |
Кого берут в протокол |
Target population for the teatment:
|
Руководитель протокола | Prof. Dr. med. Ewa Koscielniak, Prof. Dr. med. Thomas Klingebiel |
cws@klinikum-stuttgart.de | |
URL | http://www.cws.olgahospital-stuttgart.de |
С кем можно связаться |
Coordination |
Documents | |
Кто финансирует | Die Deutsche Kinderkrebsstiftung fördert das Register SoTiSaR und die CWS-2007 HR Studie. Der Förderkreis Krebskranke Kinder Stuttgart e.V. unterstützt die Ausstattung der CWS-Studienzentrale. |